Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Non-Current Debt (2016 - 2017)

Bone Biologics (BBLG) has disclosed Non-Current Debt for 2 consecutive years, with $7.2 million as the latest value for Q3 2017.

  • On a quarterly basis, Non-Current Debt rose 20.76% to $7.2 million in Q3 2017 year-over-year; TTM through Sep 2017 was $7.2 million, a 20.76% increase, with the full-year FY2016 number at $7.6 million, changed N/A from a year prior.
  • Non-Current Debt was $7.2 million for Q3 2017 at Bone Biologics, up from $6.9 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $7.6 million in Q4 2016 to a low of $5.3 million in Q1 2016.